UXI1 Stock Chart & Stats
€1.48
€0.00(0.00%)
At close: 4:00 PM EDT
€1.48
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.11 - €4.93
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.08M
Enterprise Value€1.30
Total Cash (Recent Filing)€3.79M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding6,622,794
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)4.33
P/FCF Ratio-0.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-234.27
Revenue Forecast (FY)€87.15K
Bulls Say, Bears Say
Bulls Say
Improving Revenue TractionStrong year-over-year revenue growth indicates improving commercialization and customer adoption compared with prior years. If this trajectory persists, expanding sales can provide operating leverage and create a broader base from which the company may eventually improve profitability.
Low Financial LeverageAn essentially debt-free balance sheet limits creditor pressure and reduces the burden of interest and refinancing obligations. Positive equity also provides a stronger financial foundation for executing the business transition, although continued losses could still weaken this cushion.
Fire Safety Business TransitionThe shift toward fire safety protection and equipment distribution gives BGMS a defined commercial focus after moving away from its former biopharmaceutical emphasis. A clearer operating model, combined with cost streamlining under new management, could support more consistent execution.
Bears Say
Severe UnprofitabilityProfitability remains far from sustainable, with operating losses exceeding revenue and a very low gross margin. These results show that the current business model has not yet achieved a scalable cost structure, leaving earnings highly dependent on substantial improvement in sales economics.
Persistent Cash BurnNegative operating and free cash flow means the company continues to consume cash while running and investing in the business. Although operating cash burn improved from 2025, ongoing funding needs could constrain strategic flexibility until operations move materially closer to breakeven.
Dilution And Ownership RiskThe proposed business combination creates a substantial ownership risk for existing shareholders if completed on the stated terms. Such a sharp reduction in relative ownership could limit their participation in future value creation and materially alter the company’s capital structure.
Bio Green Med Solution News
UXI1 FAQ
What was Bio Green Med Solution’s price range in the past 12 months?
Bio Green Med Solution lowest stock price was €1.11 and its highest was €4.93 in the past 12 months.
What is Bio Green Med Solution’s market cap?
Bio Green Med Solution’s market cap is €6.08M.
When is Bio Green Med Solution’s upcoming earnings report date?
Bio Green Med Solution’s upcoming earnings report date is Nov 18, 2026 which is in 61 days.
How were Bio Green Med Solution’s earnings last quarter?
Bio Green Med Solution released its earnings results on Aug 12, 2026. The company reported -€0.066 earnings per share for the quarter.
Is Bio Green Med Solution overvalued?
According to Wall Street analysts Bio Green Med Solution’s price is currently Overvalued.
Does Bio Green Med Solution pay dividends?
Bio Green Med Solution does not currently pay dividends.
What is Bio Green Med Solution’s EPS estimate?
Bio Green Med Solution’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio Green Med Solution have?
Bio Green Med Solution has 6,622,794 shares outstanding.
What happened to Bio Green Med Solution’s price movement after its last earnings report?
Bio Green Med Solution reported an EPS of -€0.066 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bio Green Med Solution?
Currently, no hedge funds are holding shares in DE:UXI1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio Green Med Solution
Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitters Sdn. Bhd., a Malaysian firm known for its fire safety products and services. BGMS is committed to driving progress in biopharmaceutical research and developing cutting-edge fire safety solutions, striving to deliver enduring value to its investors.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Rein Therapeutics
―
Bluejay Diagnostics
―
Neuphoria Therapeutics
―